" class="no-js "lang="en-US"> Applied BioMath, LLC Announces Collaboration with BYOMass™ for Systems Pharmacology Modeling in Oncology - Medtech Alert
Friday, May 24, 2024

Applied BioMath, LLC Announces Collaboration with BYOMass™ for Systems Pharmacology Modeling in Oncology

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with BYOMass, Inc. for systems pharmacology modeling in chronic diseases. BYOMass is a preclinical stage pharmaceutical company focused on the TGF-ß superfamily.

“We chose Applied BioMath given their proven track record of helping companies identify ideal therapeutic properties and platforms,” said Margaret Jackson, D.Phil., Founder and CEO of BYOMass. “We hope that this collaboration will help us identify the properties of a lead candidate as efficiently as possible and aid in the design of future studies.”

Applied BioMath employs a rigorous fit-for-purpose model development process which quantitatively integrates knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms.  Their approach employs proprietary algorithms and software that were designed specifically for systems pharmacology model development, simulation, and analysis.

“We often work with early-stage companies to help them understand what their therapeutic needs to look like in order to be best in class,” said John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath. “We look forward to collaborating with BYOMass and helping them decide next steps for this project.”

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more